14.45MMarket Cap-0.77P/E (TTM)
1.4600High1.3800Low19.61KVolume1.4600Open1.4800Pre Close27.58KTurnover0.28%Turnover RatioLossP/E (Static)10.17MShares3.260052wk High1.14P/B9.96MFloat Cap1.350052wk Low--Dividend TTM7.01MShs Float77.4000Historical High--Div YieldTTM5.41%Amplitude1.3250Historical Low1.4060Avg Price1Lot Size
Cocrystal Pharma Stock Forum
Cocrystal Pharma Pushes Forward with Antiviral Programs Despite $17.5M Loss
Cocrystal Pharma Reports Phase 1 Results with Oral, Broad-Acting Antiviral Drug CDI-988 for Prophylaxis and Treatment of Norovirus, Coronaviruses and Other Viral Infections
Wednesday, 8th January at 8:00 am
• Data show favorable safety and tolerability with dosing up to 800 mg for 10 days
• Plans to initiate human challenge study in 2025 in norovirus-infected subjects
BOTHELL, Wash., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ: COCP) ("Cocry...
$Ascent Solar Technologies (ASTI.US)$- Following delivery and the successful completion of the on-orbi...
Cocrystal Pharma Reports Favorable Results from Single-Ascending Dose Cohorts of Phase 1 Study with CDI-988, its Oral Pan-Viral Norovirus/Coronavirus Protease Inhibitor
Cocrystal Pharma (Nasdaq: COCP) reported favorable safety and tolerability results from the single-ascending dose (SAD) cohorts of its Phase 1 study for CDI-988, an oral pan-viral norovirus/coronavirus protease inhibitor.
The study, conducted in Australia, evaluated doses ranging from 100 mg to 60...
NEWS
Enrollment Completed in Phase 2a Study with Cocrystal Pharma’s Oral Antiviral Candidate CC-42344 for Pandemic and Seasonal Influenza
No comment yet